Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Coherus BioSciences Inc

Current price
2.07 USD +0.05 USD (+2.48%)
Last closed 2 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 251 352 224 USD
Yield for 12 month -74.03 %
21.11.2021 - 28.11.2021

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Address: 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

10.43 USD

P/E ratio

Dividend Yield

Current Year

+257 244 000 USD

Last Year

+211 042 000 USD

Current Quarter

+91 524 000 USD

Last Quarter

+74 568 000 USD

Current Year

+94 461 000 USD

Last Year

+140 959 000 USD

Current Quarter

+5 894 000 USD

Last Quarter

+41 865 000 USD

Key Figures CHRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -189 408 000 USD
Operating Margin TTM -98.78 %
PE Ratio
Return On Assets TTM -21.75 %
PEG Ratio
Return On Equity TTM -1657.06 %
Wall Street Target Price 10.43 USD
Revenue TTM 257 244 000 USD
Book Value -1.72 USD
Revenue Per Share TTM 2.73 USD
Dividend Share
Quarterly Revenue Growth YOY 101.8 %
Dividend Yield
Gross Profit TTM -58 399 000 USD
Earnings Share -2.53 USD
Diluted Eps TTM -2.53 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY -75.5 %
Profit Margin -92.48 %

Dividend Analytics CHRS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CHRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CHRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 6.7981
Enterprise Value Revenue 2.3886
Price Sales TTM 0.9771
Enterprise Value EBITDA -3.1683
Price Book MRQ 73.1897

Financials CHRS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CHRS

For 52 weeks

1.43 USD 8.34 USD
50 Day MA 2.39 USD
Shares Short Prior Month 25 912 476
200 Day MA 3.23 USD
Short Ratio 7.6
Shares Short 23 447 884
Short Percent 24.88 %

Dynamics of changes in the value of assets




399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds



207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics



2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics